NASDAQ:ICLR - Nasdaq - IE0005711209 - Common Stock - Currency: USD
Overall ICLR gets a fundamental rating of 5 out of 10. We evaluated ICLR against 54 industry peers in the Life Sciences Tools & Services industry. Both the profitability and the financial health of ICLR get a neutral evaluation. Nothing too spectacular is happening here. ICLR has a correct valuation and a medium growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 4.53% | ||
ROE | 7.98% | ||
ROIC | 6.71% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 14.54% | ||
PM (TTM) | 9.25% | ||
GM | 29.08% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.36 | ||
Debt/FCF | 3.23 | ||
Altman-Z | 2.23 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.27 | ||
Quick Ratio | 1.27 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 14.14 | ||
Fwd PE | 12.89 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 14.05 | ||
EV/EBITDA | 10.91 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
187.01
-8 (-4.1%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 14.14 | ||
Fwd PE | 12.89 | ||
P/S | 1.81 | ||
P/FCF | 14.05 | ||
P/OCF | 12.1 | ||
P/B | 1.56 | ||
P/tB | N/A | ||
EV/EBITDA | 10.91 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 4.53% | ||
ROE | 7.98% | ||
ROCE | 8.49% | ||
ROIC | 6.71% | ||
ROICexc | 6.97% | ||
ROICexgc | 100.08% | ||
OM | 14.54% | ||
PM (TTM) | 9.25% | ||
GM | 29.08% | ||
FCFM | 12.91% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.36 | ||
Debt/FCF | 3.23 | ||
Debt/EBITDA | 2.08 | ||
Cap/Depr | 39.01% | ||
Cap/Sales | 2.07% | ||
Interest Coverage | 250 | ||
Cash Conversion | 75.48% | ||
Profit Quality | 139.54% | ||
Current Ratio | 1.27 | ||
Quick Ratio | 1.27 | ||
Altman-Z | 2.23 |